Laura F Michael1, Joanne E Curran2,3, Nicholas B Blackburn2,3,4, Peter J Meikle5, Juan M Peralta2,3,4, Satish Kumar2,3, Ana C Leandro2,3, Melissa A Bellinger1, Corey Giles5, Kevin Huynh5, Michael C Mahaney2,3, Harald H H Göring2,3, John L VandeBerg2,3, Sarah Williams-Blangero2,3, David C Glahn6,7, Ravindranath Duggirala2,3, John Blangero2,3. 1. Eli Lilly and Company, Indianapolis, IN (M.A.B., L.F.M.). 2. South Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX. 3. Department of Human Genetics (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX. 4. Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia (N.B.B., J.M.P.). 5. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M., C.G., K.H.). 6. Department of Psychiatry, Boston Children's Hospital and Harvard Medical School, Boston, MA (D.C.G.). 7. Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT (D.C.G.).
Abstract
BACKGROUND: The identification and understanding of therapeutic targets for atherosclerotic cardiovascular disease is of fundamental importance given its global health and economic burden. Inhibition of ANGPTL3 (angiopoietin-like 3) has demonstrated a cardioprotective effect, showing promise for atherosclerotic cardiovascular disease treatment, and is currently the focus of ongoing clinical trials. Here, we assessed the genetic basis of variation in ANGPTL3 levels in the San Antonio Family Heart Study. METHODS: We assayed ANGPTL3 protein levels in ≈1000 Mexican Americans from extended pedigrees. By drawing upon existing plasma lipidome profiles and genomic data we conducted analyses to understand the genetic basis to variation in ANGPTL3 protein levels, and accordingly the correlation with the plasma lipidome. RESULTS: In a variance components framework, we identified that variation in ANGPTL3 was significantly heritable (h2=0.33, P=1.31×10-16). To explore the genetic basis of this heritability, we conducted a genome-wide linkage scan and identified significant linkage (logarithm of odds =6.18) to a locus on chromosome 1 at 90 centimorgans, corresponding to the ANGPTL3 gene location. In the genomes of 23 individuals from a single pedigree, we identified a loss-of-function variant, rs398122988 (N121Kfs*2), in ANGPTL3, that was significantly associated with lower ANGPTL3 levels (β=-1.69 SD units, P=3.367×10-13), and accounted for the linkage signal at this locus. Given the known role of ANGPTL3 as an inhibitor of endothelial and lipoprotein lipase, we explored the association of ANGPTL3 protein levels and rs398122988 with the plasma lipidome and related phenotypes, identifying novel associations with phosphatidylinositols. CONCLUSIONS: Variation in ANGPTL3 protein levels is heritable and under significant genetic control. Both ANGPTL3 levels and loss-of-function variants in ANGPTL3 have significant associations with the plasma lipidome. These findings further our understanding of ANGPTL3 as a therapeutic target for atherosclerotic cardiovascular disease.
BACKGROUND: The identification and understanding of therapeutic targets for atherosclerotic cardiovascular disease is of fundamental importance given its global health and economic burden. Inhibition of ANGPTL3 (angiopoietin-like 3) has demonstrated a cardioprotective effect, showing promise for atherosclerotic cardiovascular disease treatment, and is currently the focus of ongoing clinical trials. Here, we assessed the genetic basis of variation in ANGPTL3 levels in the San Antonio Family Heart Study. METHODS: We assayed ANGPTL3 protein levels in ≈1000 Mexican Americans from extended pedigrees. By drawing upon existing plasma lipidome profiles and genomic data we conducted analyses to understand the genetic basis to variation in ANGPTL3 protein levels, and accordingly the correlation with the plasma lipidome. RESULTS: In a variance components framework, we identified that variation in ANGPTL3 was significantly heritable (h2=0.33, P=1.31×10-16). To explore the genetic basis of this heritability, we conducted a genome-wide linkage scan and identified significant linkage (logarithm of odds =6.18) to a locus on chromosome 1 at 90 centimorgans, corresponding to the ANGPTL3 gene location. In the genomes of 23 individuals from a single pedigree, we identified a loss-of-function variant, rs398122988 (N121Kfs*2), in ANGPTL3, that was significantly associated with lower ANGPTL3 levels (β=-1.69 SD units, P=3.367×10-13), and accounted for the linkage signal at this locus. Given the known role of ANGPTL3 as an inhibitor of endothelial and lipoprotein lipase, we explored the association of ANGPTL3 protein levels and rs398122988 with the plasma lipidome and related phenotypes, identifying novel associations with phosphatidylinositols. CONCLUSIONS: Variation in ANGPTL3 protein levels is heritable and under significant genetic control. Both ANGPTL3 levels and loss-of-function variants in ANGPTL3 have significant associations with the plasma lipidome. These findings further our understanding of ANGPTL3 as a therapeutic target for atherosclerotic cardiovascular disease.
Authors: Claire Bellis; Hemant Kulkarni; Manju Mamtani; Jack W Kent; Gerard Wong; Jacquelyn M Weir; Christopher K Barlow; Vincent Diego; Marcio Almeida; Thomas D Dyer; Harald H H Göring; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Sarah Williams-Blangero; Peter J Meikle; John Blangero; Joanne E Curran Journal: Circ Cardiovasc Genet Date: 2014-11-02
Authors: Kaushala S Jayawardana; Piyushkumar A Mundra; Corey Giles; Christopher K Barlow; Paul J Nestel; Elizabeth H Barnes; Adrienne Kirby; Peter Thompson; David R Sullivan; Zahir H Alshehry; Natalie A Mellett; Kevin Huynh; Malcolm J McConville; Sophia Zoungas; Graham S Hillis; John Chalmers; Mark Woodward; Ian C Marschner; Gerard Wong; Bronwyn A Kingwell; John Simes; Andrew M Tonkin; Peter J Meikle Journal: JCI Insight Date: 2019-07-11
Authors: Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh Journal: JAMA Date: 2009-11-11 Impact factor: 56.272
Authors: Frederick J Raal; Robert S Rosenson; Laurens F Reeskamp; G Kees Hovingh; John J P Kastelein; Paolo Rubba; Shazia Ali; Poulabi Banerjee; Kuo-Chen Chan; Daniel A Gipe; Nagwa Khilla; Robert Pordy; David M Weinreich; George D Yancopoulos; Yi Zhang; Daniel Gaudet Journal: N Engl J Med Date: 2020-08-20 Impact factor: 91.245
Authors: Nathan O Stitziel; Amit V Khera; Xiao Wang; Andrew J Bierhals; A Christina Vourakis; Alexandra E Sperry; Pradeep Natarajan; Derek Klarin; Connor A Emdin; Seyedeh M Zekavat; Akihiro Nomura; Jeanette Erdmann; Heribert Schunkert; Nilesh J Samani; William E Kraus; Svati H Shah; Bing Yu; Eric Boerwinkle; Daniel J Rader; Namrata Gupta; Philippe M Frossard; Asif Rasheed; John Danesh; Eric S Lander; Stacey Gabriel; Danish Saleheen; Kiran Musunuru; Sekar Kathiresan Journal: J Am Coll Cardiol Date: 2017-04-03 Impact factor: 24.094
Authors: Gemma Cadby; Corey Giles; Phillip E Melton; Kevin Huynh; Natalie A Mellett; Thy Duong; Anh Nguyen; Michelle Cinel; Alex Smith; Gavriel Olshansky; Tingting Wang; Marta Brozynska; Mike Inouye; Nina S McCarthy; Amir Ariff; Joseph Hung; Jennie Hui; John Beilby; Marie-Pierre Dubé; Gerald F Watts; Sonia Shah; Naomi R Wray; Wei Ling Florence Lim; Pratishtha Chatterjee; Ian Martins; Simon M Laws; Tenielle Porter; Michael Vacher; Ashley I Bush; Christopher C Rowe; Victor L Villemagne; David Ames; Colin L Masters; Kevin Taddei; Matthias Arnold; Gabi Kastenmüller; Kwangsik Nho; Andrew J Saykin; Xianlin Han; Rima Kaddurah-Daouk; Ralph N Martins; John Blangero; Peter J Meikle; Eric K Moses Journal: Nat Commun Date: 2022-06-06 Impact factor: 17.694